57030-77-0

Basic information

• Product Name: CITRONELLIC ACID
• Synonyms: Brn 1722960;Einecs 207-939-7;Fema no. 3142;Rhodinolic acid
• CAS NO: 57030-77-0
• Molecular Formula: C10H18O2
• Molecular Weight: 170.2538
• Mol File: 57030-77-0.mol
• Article Data: 65

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CITRONELLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: CITRONELLIC ACID(57030-77-0)
• EPA Substance Registry System: CITRONELLIC ACID(57030-77-0)

Safety Data

• RIDADR: 2810
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 57030-77-0(Hazardous Substances Data)

Upstream product

• 106-22-9 Citronellol 
• 3068-88-0 4-methyloxetan-2-one 
• 37586-57-5 4-methyl-3-pentenylmagnesium bromide 
• 106-23-0 3,7-dimethyl-oct-6-enal 
• 1117-61-9 (3R)-citronellol 
• 7647-01-0 hydrogenchloride 
• 89-82-7 pulegone 
• 2385-77-5 (R)-Citronellal 
• 55050-39-0 3-Methylene-7-methyloct-6-enoic Acid 
• 5949-05-3 (S)-Citronellal 
• 4613-38-1 nerolic acid 
• 459-80-3 geranic acid 
• 99863-63-5 6-amino-3,7-dimethyl-octanoic acid 
• 5392-40-5 (E/Z)-3,7-dimethyl-2,6-octadienal 

Downstream Products

• 3664-64-0 rac-4,8-dimethyl-7-nonen-2-one 
• 67214-54-4 (R)-citronellyl tosylate 
• 70200-31-6 (R)-4-methyl-6-(toluene-4-sulfonyloxy)-hexanal 
• 56046-15-2 (R)-7-hydroxycitronellic acid 
• 1373120-70-7 (2S,3R,5S)-2-((R)-but-3-en-2-yl)-5-methyl-1-tosylpiperidin-3-ol 
• 1373120-69-4 (2S,3R,5S)-2-((S)-but-3-en-2-yl)-5-methyl-1-tosylpiperidin-3-ol 

Relevant articles and documents

Modulation of the Passive Permeability of Semipeptidic Macrocycles: N- And C-Methylations Fine-Tune Conformation and Properties

Incorporating small modifications to peptidic macrocycles can have a major influence on their properties. For instance, N-methylation has been shown to impact permeability. A better understanding of the relationship between permeability and structure is of key importance as peptidic drugs are often associated with unfavorable pharmacokinetic profiles. Starting from a semipeptidic macrocycle backbone composed of a tripeptide tethered head-to-tail with an alkyl linker, we investigated two small changes: peptide-to-peptoid substitution and various methyl placements on the nonpeptidic linker. Implementing these changes in parallel, we created a collection of 36 compounds. Their permeability was then assessed in parallel artificial membrane permeability assay (PAMPA) and Caco-2 assays. Our results show a systematic improvement in permeability associated with one peptoid position in the cycle, while the influence of methyl substitution varies on a case-by-case basis. Using a combination of molecular dynamics simulations and NMR measurements, we offer hypotheses to explain such behavior.

Macrocyclic compounds as EGFR inhibitors and uses thereof

The invention belongs to the field of pharmaceutical chemistry and relates to a macrocyclic compound serving as EGFR inhibitor and application thereof, in particular to a compound shown in the formula (I) or an isomer thereof. Pharmaceutically acceptable salts, solvates, crystalline or prodrugs, processes for their preparation and include pharmaceutical compositions of these compounds and the use of these compounds or compositions for the treatment EGFR-mediated diseases.

MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.